Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Preliminary phase II/III data disclosed on fosbretabulin plus chemotherapy in ATC

Nov. 5, 2010

MLN-8237 shows promise in epithelial ovarian, fallopian tube and primary peritoneal carcinoma

Nov. 5, 2010

Lucinactant receives FDA orphan drug status in CF after encouraging phase II trial results

Nov. 5, 2010

Intradermal and intramuscular Fluzone are equally immunogenic

Nov. 5, 2010

CMX-001 effective in immunocompromised adenovirus-infected patients

Nov. 4, 2010

Adjuvanted VZV subunit vaccine gE/AS01B is more immunogenic than Varilrix

Nov. 4, 2010

Panobinostat has antitumor activity in phase II trial in SCLC

Nov. 4, 2010

AMG-386 is active in renal cell carcinoma and ovarian cancer

Nov. 4, 2010

ENB-0040 shows promise to treat hypophosphatasia in children

Nov. 4, 2010

Clinical data reported on cilengitide in NSCLC and glioblastoma

Nov. 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...